A Phase 2b Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderately Severe Diabetic Neuropathy.
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2017
At a glance
- Drugs SB 509 (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Sponsors Sangamo BioSciences
- 18 Apr 2016 Status changed from active, no longer recruiting to completed.
- 18 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 18 May 2015 Planned primary completion date changed from 1 Dec 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.